MyFinsight
Home
Compare
Blog
About
Odyssey Therapeutics, Inc. (ODTX)
Odyssey Therapeutics, Inc. (ODTX)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Cash Flow Overview
Free Cash flow
-$34,694K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from the issuance of co...
Maturities of marketable securit...
Change in fair value of continge...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Net loss
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
Net loss
-52,788
-38,262
Depreciation and amortization
1,043
1,171
Loss from disposal of property and equipment
-639
33
Right-of-use asset impairment expense
0
0
Accretion of discount on marketable securities
-71
296
Stock-based compensation expense
5,671
2,587
Non-cash rent expense
878
879
Change in fair value of contingent consideration and warrant liability
8,804
109
Prepaid expenses and other current assets
1,591
-3
Other non-current assets
-1,469
1,686
Accounts payable
-797
484
Lease liabilities
-1,255
-1,225
Accrued expenses and other current liabilities
3,348
-4,766
Net cash used in operating activities
-34,508
-41,035
Maturities of marketable securities
34,950
34,950
Purchases of marketable securities
246,489
-
Proceeds from sale of property and equipment
281
0
Purchases of property and equipment
186
148
Net cash (used in) provided by investing activities
-211,444
34,802
Proceeds from the exercise of common stock options
586
651
Payment of deferred offering costs
-
143
Proceeds from the exercise of common stock warrants
0
-
Principal payments on finance leases
46
24
Proceeds from the issuance of common stock upon ipo, net of offering costs
291,477
-
Proceeds from the issuance of convertible preferred stock, net of issuance costs
0
-
Net cash provided by financing activities
292,160
484
Effect of exchange rate changes on cash, cash equivalents, and restricted cash
104
24
Increase in cash, cash equivalents and restricted cash
46,312
-5,725
Cash, cash equivalents and restricted cash, beginning of period
39,172
44,897
Cash, cash equivalents and restricted cash, end of period
85,484
-
Cash and cash equivalents, end of period
82,031
-
Restricted cash, included in other non-current assets, end of period
3,453
-
Total cash, cash equivalents and restricted cash, end of period
85,484
39,172
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from the
issuance of common stock...
$291,477K
Proceeds from the
exercise of common stock...
$586K
Net cash provided by
financing activities
$292,160K
Effect of exchange rate
changes on cash, cash...
$104K
Increase in cash, cash
equivalents and restricted...
$46,312K
Canceled cashflow
$245,952K
Maturities of marketable
securities
$34,950K
Proceeds from sale of
property and equipment
$281K
Change in fair value of
contingent consideration...
$8,804K
Stock-based compensation
expense
$5,671K
Accrued expenses and
other current...
$3,348K
Other non-current
assets
-$1,469K
Depreciation and
amortization
$1,043K
Non-cash rent expense
$878K
Loss from disposal of
property and equipment
-$639K
Accretion of discount on
marketable securities
-$71K
Net cash (used in)
provided by investing...
-$211,444K
Net cash used in
operating activities
-$34,508K
Canceled cashflow
$35,231K
Canceled cashflow
$21,923K
Purchases of marketable
securities
$246,489K
Net loss
-$52,788K
Purchases of property and
equipment
$186K
Prepaid expenses and
other current assets
$1,591K
Lease liabilities
-$1,255K
Accounts payable
-$797K
Buy us a coffee